



Carlo R Largiadèr

Contact

Carlo R Largiadèr

Publications (10)

Kueng N, Arcioni S, Sandberg F, Kuhn C, Banz V, Largiadèr C, Sidler D, Amstutz U. Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients. *Front Genet* 2023; 14:1089830.

Schmulenson E, Bovet C, Theurillat R, Decosterd L, Largiadèr C, Prost J, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Jörger M, Jaehde U. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). *Br J Clin Pharmacol* 2022; 88:5336–5347.

Begré U, Jörger M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. *Front Pharmacol* 2022; 13:885259.

Dietmann A, Wenz E, van der Meer J, Ringli M, Warncke J, Edwards E, Schmidt M, Bernasconi C, Nirkko A, Strub M, Miano S, Manconi M, Acker J, Von Manitius S, Baumann C, Valko P, Yilmaz B, Brunner A, Tzovara A, Zhang Z, Largiadèr C, Tafti M, Latorre D, Sallusto F, Khatami R, Bassetti C. The Swiss Primary Hypersomnolence and Narcolepsy Cohort study (SPHYNCS): Study protocol for a prospective, multicentre cohort observational study. *J Sleep Res* 2021; 30:e13296.

Schaerer D, Froehlich T, Hamzic S, Offer S, Diasio R, Jörger M, Amstutz U, Largiadèr C. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. *J Pers Med* 2020; 10

Hamzic S, Amstutz U, López-Fernández L, García-González X, Schellens J, Meulendijks D, Thomlinson I, Palles C, Aebi S, Jörger M, Froehlich T, Kummer D, Largiadèr C. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. *Pharmacol Res* 2019; 152:104594.

Kummer D, Froehlich T, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr C. Dihydropyrimidinase and β -ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. *Pharmacogenomics* 2015; 16:1367–77.

Amstutz U, Offer S, Sistonen J, Joerger M, Diasio R, Largiadèr C. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. *Clin Cancer Res* 2015; 21:2038–44.

Froehlich T, Amstutz U, Aebi S, Jörger M, Largiadèr C. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. *Int J Cancer* 2014; 136:730–9.

Büchel B, Sistonen J, Jörger M, Aebi Y, Schürch S, Largiadèr C. Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients. *Clin Chem Lab Med* 2013; 51:1681–8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch